What is Blaze Bioscience?
Blaze Bioscience is a privately held biotechnology company focused on enhancing the lives of cancer patients, particularly children undergoing brain cancer surgery. The company leverages its proprietary Tumor Paint technology and the CANVAS imaging system to significantly improve the detection, removal, and subsequent treatment of various cancers. Their core mission is to advance cancer care, making it more sensitive, reliable, and accessible for healthcare providers and institutions globally.
How much funding has Blaze Bioscience raised?
Blaze Bioscience has raised a total of $17M across 7 funding rounds:
Debt
$725K
Series A
$5M
Series B
$9M
Debt
$991K
Debt
$554K
Debt
$350K
Debt
$421K
Debt (2011): $725K, investors not publicly disclosed
Series A (2012): $5M, investors not publicly disclosed
Series B (2013): $9M, investors not publicly disclosed
Debt (2015): $991K, investors not publicly disclosed
Debt (2017): $554K, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
Debt (2021): $421K led by PPP
What's next for Blaze Bioscience?
With the recent major strategic investment, Blaze Bioscience is poised for significant expansion. The capital infusion is anticipated to fuel further research and development of its Tumor Paint and CANVAS technologies, potentially broadening their application across a wider range of cancer types and surgical procedures. This strategic financing suggests a focus on scaling operations, forging key partnerships within the healthcare ecosystem, and advancing towards broader clinical adoption and commercialization, solidifying its position in the competitive oncology market.
See full Blaze Bioscience company page
